State Attorney General George Jepsen is investigating the pricing practices of at least two companies that manufacturer a generic heart drug called digoxin, according to filings with the U.S. Securities and Exchange Commission.
Lannett Company Inc., a major U.S. distributor of the drug, said Tuesday that it had conducted an internal review of its pricing practices and determined that it “acted in compliance with applicable laws and regulations with regard to the pricing of digoxin.”
The Philadelphia company was subpoenaed by Jepsen in July for information related to whether the company engaged in any activities that resulted in fixing, maintaining or controlling prices of the drug. The probe also asked if the company had divided up sales territories for the drug, which would violate state law.
A spokeswoman for Jepsen declined comment Tuesday.
Lannett said it reviewed more than 700,000 documents to conclude it had done no wrong, but said it will continue to cooperate with Jepsen’s investigation.
California’s Impax Laboratories also reported receiving a subpoena from Jepsen.
The New York Times reported in July that digoxin prices had nearly doubled or worse since last year.
Earlier this month, Jepsen got involved in another generic drug case, filing comments with the U.S. Food and Drug Administration in support of speeding a generic version of heartburn drug Nexium to market.
